<DOC>
	<DOCNO>NCT02227888</DOCNO>
	<brief_summary>This Phase 1 study F508del-CFTR homozygous CF patient conduct assess pharmacokinetics absorption dynamic N91115 compare healthy subject order identify initial start dose Phase 2 trial .</brief_summary>
	<brief_title>PK Study N91115 Cystic Fibrosis Patients</brief_title>
	<detailed_description>This open-label pharmacokinetic ( PK ) study twice daily dos 50 mg N91115 administer 14 day F508del-CFTR homozygous CF patient . Six patient plan enrollment . Each patient undergo screening ( Day 28 Day 3 ) , eligible , return clinical site Day 1 optionally Day 1 . Eligibility reconfirm patient admitted clinical research unit ( CRU ) . Patients stay overnight Day 1 Day 2 discharge Day 2 procedure assessment complete . Patients return CRU outpatient Days 4 , 7 , 11 , 14 , 15 PK sample collection assessment . They receive oral dose investigational medicinal product ( IMP ) , N91115 , twice daily Days 1 14 follow PK Day 15 . Telephone call assess safety ensure compliance dose make day patient make clinic visit ( Days 3 , 5 , 6 , 8 , 9 , 10 , 12 , 13 ) . Follow-up safety call make Day 21 ( adverse event ) Day 28 ( serious adverse event ) . Participation individual patient may last approximately 56 day time screen end-of-study ( Day 28 ) follow-up call .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>1 . Confirmed diagnosis CF , homozygous F508delCFTR mutation 2 . Weight ≥ 40 kg screen 3 . FEV1 ≥ 40 % predict normal age , gender , height ( Hankinson standard ) pre postbronchodilator value , screen 4 . Hematology , clinical chemistry , urinalysis result clinically significant abnormality would interfere study assessment screen 1 . History illness condition opinion investigator could confound result study pose additional risk administer IMP 2 . Any acute infection , include acute upper low respiratory infection pulmonary exacerbation require treatment hospitalization within 4 week Study Day 1 3 . Any change chronic therapy CF lung disease ( e.g. , Ibuprofen , Pulmozyme® , hypertonic saline , Azithromycin , TOBI® , Cayston® ) within 4 week Study Day 1 4 . History , include screen assessment , ventricular tachycardia ventricular arrhythmias 5 . History , include screen assessment , prolong QT and/or QTcF ( Fridericia 's correction ) interval ( &gt; 450 msec ) 6 . History solid organ hematological transplantation 7 . History alcohol abuse drug addiction ( include cannabis , cocaine , opioids ) year prior screen 8 . Use continuous ( 24 hr/day ) nocturnal supplemental oxygen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>CF</keyword>
	<keyword>F508Del</keyword>
	<keyword>Cavosonstat</keyword>
	<keyword>N91115</keyword>
</DOC>